Your browser doesn't support javascript.
loading
Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol.
Bleeker, L; Kouwenhoven, M C M; de Heer, I; Lissenberg-Witte, B I; Gijsbers, A H; Dubbink, H J; Kros, J M; Gijtenbeek, J M M; Kurt, E; van der Rijt, C C D; Swaak-Kragten, A T; de Vos, F Y; van der Weide, H L; French, P J; van den Bent, M J; Wesseling, P; Bromberg, J E C.
Afiliación
  • Bleeker L; Brain Tumor Center Amsterdam, Department of Neurology, Amsterdam UMC, Amsterdam, The Netherlands. l.bleeker@olvg.nl.
  • Kouwenhoven MCM; Brain Tumor Center Amsterdam, Department of Neurology, Amsterdam UMC, Amsterdam, The Netherlands.
  • de Heer I; Brain Tumor Center, Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Lissenberg-Witte BI; Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, The Netherlands.
  • Gijsbers AH; The Nationwide Network and Registry of Histopathology and Cytopathology in the Netherlands (PALGA), Houten, The Netherlands.
  • Dubbink HJ; Brain Tumor Center, Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Kros JM; Brain Tumor Center, Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Gijtenbeek JMM; Department of Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • Kurt E; Department of Neurosurgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • van der Rijt CCD; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Swaak-Kragten AT; Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • de Vos FY; Cancer Center, Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van der Weide HL; University Medical Center Groningen, Department of Radiation Oncology, University of Groningen, Groningen, The Netherlands.
  • French PJ; Brain Tumor Center, Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • van den Bent MJ; Brain Tumor Center, Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Wesseling P; Department of Pathology, Amsterdam University Medical Centers/VUmc, Amsterdam, The Netherlands.
  • Bromberg JEC; Laboratory for Childhood Cancer Pathology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
J Neurooncol ; 162(1): 225-235, 2023 Mar.
Article en En | MEDLINE | ID: mdl-36920679
ABSTRACT

PURPOSE:

Medulloblastoma is a rare tumor in adults. The objective of this nationwide, multicenter study was to evaluate the toxicity and efficacy of the Dutch treatment protocol for adult medulloblastoma patients.

METHODS:

Adult medulloblastoma patients diagnosed between 2010 and 2018 were identified in the Dutch rare tumors registry or nationwide pathology database. Patients with intention to treat according to the national treatment protocol were included. Risk stratification was performed based on residual disease, histological subtype and extent of disease. All patients received postoperative radiotherapy [craniospinal axis 36 Gy/fossa posterior boost 19.8 Gy (14.4 Gy in case of metastases)]. High-risk patients received additional neoadjuvant (carboplatin-etoposide), concomitant (vincristine) and adjuvant chemotherapy (carboplatin-vincristine-cyclophosphamide) as far as feasible by toxicity. Methylation profiling, and additional next-generation sequencing in case of SHH-activated medulloblastomas, were performed.

RESULTS:

Forty-seven medulloblastoma patients were identified, of whom 32 were treated according to the protocol. Clinical information and tumor material was available for 28 and 20 patients, respectively. The histological variants were mainly classic (43%) and desmoplastic medulloblastoma (36%). Sixteen patients (57%) were considered standard-risk and 60% were SHH-activated medulloblastomas. Considerable treatment reductions and delays in treatment occurred due to especially hematological and neurotoxicity. Only one high-risk patient could complete all chemotherapy courses. 5-years progression-free survival (PFS) and overall survival (OS) for standard-risk patients appeared worse than for high-risk patients (PFS 69% vs. 90%, OS 81% vs. 90% respectively), although this wasn't statistically significant.

CONCLUSION:

Combined chemo-radiotherapy is a toxic regimen for adult medulloblastoma patients that may result in improved survival.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cerebelosas / Meduloblastoma Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Humans Idioma: En Revista: J Neurooncol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cerebelosas / Meduloblastoma Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Humans Idioma: En Revista: J Neurooncol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos